Regeneron Reports No New Abnormal Bone Growth in Extended Trial

Patients showed no new abnormal bone growth in an extended Phase 3 trial of Regeneron’s recently approved rare disease drug. REGN shares rose about 2.8%, heading for their best day in over a month.